Kenya Medical Device Annual Retention: Form 4 Deadlines and Fees

Content verified on: October 30, 2026

1. Key takeaways

• All medical devices and in-vitro diagnostics must complete Annual Retention every year; the 5-year validity of the registration certificate does not exempt anyone from it (section 2.11 of the Guidelines).
• Retention is applied for on Form 4 (regulation 8 of LN 100 of 2022) and must be accompanied by a copy of a valid GMP certificate and the annual fee set out in the Second Schedule.
• There are two timing references: the procedure should be completed within 3 months before the end of the year, and the system opens for submission 60 days before the annual fee falls due (section 2.11 of the Guidelines).
• Retention runs on a calendar-year basis and the annual fee is non-refundable; non-payment can lead to suspension and cancellation.
• There are two discrepancies in the fee references: the Second Schedule does not list annual retention amounts by device class, while Table 6 of the Guidelines lists imported Class A and B at USD 50, Class C and D at USD 300, and locally manufactured devices uniformly at USD 50.

2. Legal basis

3. Expert insights

Insight 1: The five-year certificate and yearly retention are a two-layer structure — maintaining only one layer breaks the certificate

The Kenyan certificate system is not one registration covering five years; it is a stack of a five-year certificate plus yearly retention. Regulation 8 requires licence holders to apply for retention each year on Form 4, and section 2.11 of the Guidelines confirms that all devices and in-vitro diagnostics must do so annually. GRZAN reads the essence of retention as an annual confirmation to PPB that the product has not changed in any unreported way. The declared content — product summary, manufacturing sites, approved appearance and presentation, master formula and batch size, specifications and analytical procedures, and post-registration measures — is in substance an annual compliance declaration. Missing a year is not cured by back payment: section 2.11 states directly that non-payment can lead to suspension and cancellation.

Insight 2: The 3-month and 60-day references are two different clocks and cannot substitute for each other

Section 2.11 of the Guidelines gives two timing statements: the procedure should be completed within 3 months before year end, and the system opens for submission 60 days before the annual fee falls due. GRZAN reads the first as procedural guidance to the licence holder, pointing to internal preparation, and the second as the technical window in which online submission is actually possible. They do not conflict, but when scheduling, only the latter determines whether a submission can be made, and only the former determines when to start preparing. Conflating the two treats advice as a deadline.

Insight 3: The non-refundable fee ties budgeting to portfolio-exit decisions

Section 2.11 of the Guidelines states that the annual fee is non-refundable and that retention runs on a calendar-year basis. This means that even if a product is withdrawn mid-year, or the registration is withdrawn under regulation 12, the annual fee already paid is not returned. GRZAN recommends a portfolio review before each retention window opens: for items that will definitely no longer be supplied, run the withdrawal procedure under regulation 12 and stop paying retention at the same time, rather than continuing to fund zombie registrations year after year.

Insight 4: The chain reaction of arrears reaches beyond the certificate itself

Once non-payment leads to suspension and cancellation, section 2.13 of the Guidelines requires the licence holder and all distributors to stop immediately importing and supplying the devices concerned. GRZAN notes that this duty reaches beyond the licence holder itself: clearing distributor stock, dealing with goods in transit and arranging substitute supply for hospitals all need contingency plans before the suspension takes effect, otherwise supply-chain default risk follows.

4. Practical recommendations

1. Build a retention calendar. GRZAN recommends setting a retention milestone for every registered product on a calendar-year basis, anchored to the system-opening reference (60 days before the fee falls due) and starting internal document preparation within 3 months before year end.
2. Pre-assemble the annual data set. Turn the product summary, site list, approved appearance and presentation, master formula and batch size, and specifications and analytical procedures into a reusable annual package, updating only the changed parts each year.
3. Align GMP certificate validity. Check before the retention filing that the GMP certificate is still valid; an expired certificate makes the attachment non-compliant.
4. Archive payment evidence. File the payment receipt and system acknowledgement for each annual fee by certificate number, as proof that retention fees have been paid in full when renewal comes.
5. Review the portfolio first. Assess the product portfolio before the retention window opens and start the withdrawal procedure for items slated for exit.
6. Prepare distributor contingencies. Agree with key distributors on notification duties and stock-disposal procedures should certificate status change.

5. Verification checklist

• □ Has an annual retention milestone ledger been set up for every registered product?
• □ Is the retention start scheduled within 3 months before year end?
• □ Has the 60-day system-opening window been confirmed and submission time reserved?
• □ Does the Form 4 declaration cover all six items: product summary, manufacturing sites, appearance and presentation, master formula and batch size, specifications and analytical procedures, and post-registration measures?
• □ Is a copy of a valid GMP certificate attached and within its validity?
• □ Is the annual fee budgeted on the Guidelines Table 6 reference (imported A&B USD 50, C&D USD 300; local USD 50)?
• □ Are payment receipts and system acknowledgements for the annual fee archived?
• □ Is there a contingency plan for distributor supply stoppage and stock disposal if the certificate is suspended or cancelled?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on jurisdictions such as Kenya, Nigeria, South Africa and Egypt and runs a verification mechanism built on primary regulatory sources: every regulatory conclusion it publishes relies solely on official gazettes, the original texts of regulator guidelines and public legal databases, each marked with a verification date. Any figure, timeline or amount that cannot be located in an official source is flagged as a practical estimate rather than an assumption.

GRZAN services cover: market access strategy and risk-classification assessment; preparation and review of registration dossiers (CSDT, STED and CTD formats); selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance coaching; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; regulatory intelligence subscriptions and corporate compliance ledgers.

For a Kenya market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.